Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.

Fourteen of 18 drugs exhibited nominally significant inter-subtype variability ( P < 0.05), with the exceptions being panobinostat, ruxolitinib, bortezomib and daunorubicin (Fig. 2a , Extended Data Fig. 2 and Supplementary Table 4 ).

also in 7,732 other papers

ETP showed a trend for higher venetoclax sensitivity compared to T cell ALL, although this was not statistically significant in this relatively small cohort (LC 50 0.46 versus 0.81).

also in 53,322 other papers